In Brief: Biomatrix' Hylaform
This article was originally published in The Gray Sheet
Biomatrix' Hylaform: Plans to withdraw a pre-market approval application for its viscoelastic gel, which is designed for use in removing depressed scars and facial wrinkles, the company says in a Dec. 31 release. The firm, which anticipates revising and resubmitting the PMA, is seeking to schedule a January meeting with FDA to discuss the need for additional skin test data on allergic reactions and labeling changes. Hylaform is marketed in Europe by Collagen Corp.; the product gained the CE mark in December 1995. Biomatrix submitted a PMA to FDA in August of that year ("The Gray Sheet" Oct. 2, 1995, in brief)...
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.